Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Total revenues	$ 15,583	$ 14,042
Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,838	3,597
EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,726	4,992
APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,019	5,453
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,988	6,163
Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,595	7,879
Performance Enzymes [Member]
Disaggregation of Revenue [Line Items]
Total revenues	10,087	10,729
Performance Enzymes [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,838	3,597
Performance Enzymes [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,230	1,679
Performance Enzymes [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,019	5,453
Performance Enzymes [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	7,988	6,163
Performance Enzymes [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	2,099	4,566
Novel Biotherapeutics [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,496	3,313
Novel Biotherapeutics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0
Novel Biotherapeutics [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	5,496	3,313
Novel Biotherapeutics [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0
Novel Biotherapeutics [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 5,496	$ 3,313